ABSTRACT
OBJECTIVE: To compare the efficacy and safety of a 3-day regimen of clindamycin vaginal ovules with a 7-day regimen of clindamycin vaginal cream for the treatment of bacterial vaginosis (BV). METHODS: Women with a clinical diagnosis of BV were treated with a 3-day course of clindamycin ovules or a 7-day course of clindamycin cream administered intravaginally. Three hundred and eighty-four patients received study drug and were included in the evaluable patient population (ovule group, n = 204; cream group, n = 180). Assessments included pelvic examination and diagnostic testing. Primary efficacy endpoints were a resolution of two of three diagnostic criteria at the first follow-up visit and three of three diagnostic criteria at the second. RESULTS: Cure rates in the evaluable patient population were similar between treatment groups: 53.7% (109/204) for the ovule group and 47.8% (85/180) for the cream group (p = 0.2471, 95% CI -4.1-16.0%). The most commonly reported medical event, vulvovaginal pruritus, had similar incidence in both treatment groups. CONCLUSIONS: A 3-day course of clindamycin vaginal ovules is as effective and well-tolerated as a 7-day course of clindamycin vaginal cream in the treatment of BV.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Clindamycin/administration & dosage , Vaginosis, Bacterial/drug therapy , Administration, Intravaginal , Adolescent , Adult , Anti-Bacterial Agents/adverse effects , Clindamycin/adverse effects , Drug Administration Schedule , Female , Humans , Middle Aged , Prospective Studies , Statistics, Nonparametric , Vaginal Creams, Foams, and Jellies , Vaginosis, Bacterial/microbiologyABSTRACT
OBJECTIVE: To compare the efficacy and safety of clindamycin vaginal ovules with oral metronidazole for treatment of bacterial vaginosis. METHODS: Women with bacterial vaginosis received either 100-mg ovules of clindamycin (intravaginally for 3 consecutive days) plus placebo capsules (orally twice daily for 7 days) or metronidazole 500 mg (two 250-mg capsules orally twice daily for 7 days) plus placebo ovules (intravaginally for 3 consecutive days). The sample was determined prospectively to provide a probability of.84 of correctly concluding that the rate of success for clindamycin is not more than 15% less than the expected 75% success rate for metronidazole. Clinical outcome was determined on the basis of vaginal fluid amine odor and clue cells. RESULTS: Of the 399 patients enrolled, 233 could be evaluated for efficacy. Of those, 77 (68.1%) of 113 patients were cured with clindamycin, compared with 80 (66. 7%) of 120 who were cured with metronidazole (95% confidence interval -10.6%, 13.4%; P =.810). Treatment-related adverse events were reported more frequently in the metronidazole treatment group. Systemic symptoms, such as nausea and taste perversion, accounted for most of the difference between groups. CONCLUSION: A 3-day regimen of clindamycin, given as intravaginal ovules, was as effective as and better tolerated than a 7-day regimen of oral metronidazole 500 mg, given twice daily, for treatment of bacterial vaginosis.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Clindamycin/therapeutic use , Metronidazole/therapeutic use , Vaginosis, Bacterial/drug therapy , Administration, Intravaginal , Administration, Oral , Adolescent , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Infective Agents/administration & dosage , Clindamycin/administration & dosage , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Europe , Female , Humans , Metronidazole/administration & dosage , Middle AgedABSTRACT
As part of a 60-week, open-label, nonrandomized, parallel, controlled study comparing a monthly contraceptive injection containing medroxyprogesterone acetate (MPA) 25 mg and estradiol cypionate (E(2)C) 5 mg (Lunelle Monthly Contraceptive Injection) and a norethindrone 0.5, 0.75, 1.0 mg/0.035 mg ethinyl estradiol (NET/EE) triphasic oral contraceptive (Ortho-Novum(R) 7/7/7), a longitudinal examination of lipid profiles was conducted. Lipid parameters were assessed at screening and at weeks 20, 40, and 60 (or the final visit) in 114 women using MPA/E(2)C and 93 using NET/EE (lipid analysis population). Extra blood samples were obtained at weeks 21, 22, and 23 in 61 MPA/E(2)C users and 51 NET/EE users (index-cycle analysis population) to investigate lipid changes during one cycle of use. In the index-cycle population, median changes from screening to week 60 showed a decrease in apolipoprotein (apo) A-I and apo A-II in both groups. MPA/E(2)C users had a decrease in total cholesterol (C), total triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), with maintenance of the total C/HDL-C ratio. NET/EE users showed an increase in total C and LDL-C, with no change in HDL-C or the total C/HDL-C ratio. Within the index cycle (weeks 20 to 23), median changes in lipid values in both MPA/E(2)C and NET/EE users were generally greatest during the first week after the injection or the start of the pill pack. The results of this first longitudinal examination of serum lipids in US women using MPA/E(2)C confirm earlier findings in women in other countries. However, a direct comparison of the effects of MPA/E(2)C and NET/EE on lipid profiles was not possible in this study because of its design and because of the baseline and pharmacokinetic/pharmacodynamic differences between the two contraceptive groups. The results of this analysis showed that, although overall lipid values decreased, including a significant decrease in HDL cholesterol, the maintenance of the total-C/HDL-C ratio suggests that the effect of MPA/E(2)C on lipid parameters may not negatively affect CVD risk over 1 year of use. However, these results warrant further investigation, given the nature of this trial.
Subject(s)
Contraceptive Agents, Female/adverse effects , Contraceptives, Oral, Combined/adverse effects , Estradiol/analogs & derivatives , Lipids/blood , Medroxyprogesterone Acetate/adverse effects , Mestranol/adverse effects , Norethindrone/adverse effects , Apolipoprotein A-I/analysis , Apolipoprotein A-II/blood , Apolipoproteins B/blood , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Contraceptive Agents, Female/administration & dosage , Contraceptives, Oral, Combined/administration & dosage , Drug Combinations , Estradiol/administration & dosage , Estradiol/adverse effects , Female , Humans , Medroxyprogesterone Acetate/administration & dosage , Mestranol/administration & dosage , Norethindrone/administration & dosage , Triglycerides/bloodABSTRACT
OBJECTIVE: The purpose of this study was to compare the clinical efficacy and safety of trospectomycin sulfate with that of clindamycin phosphate, both with aztreonam, for the treatment of obstetric and gynecologic infections. METHODS: In a double-blind, multicenter, prospective randomized study, 579 patients with either endometritis following cesarean delivery or pelvic cellulitis following hysterectomy were enrolled and received medication. Administered was either trospectomycin sulfate 500 mg IV every 8 h or clindamycin phosphate 900 mg IV every 8 h in a 1:1 randomization ratio. Both groups of patients received aztreonam 1 g IV every 8 h. The patients were followed for clinical responses and side effects. RESULTS: The cure rate for the trospectomycin sulfate arm was 91.8% and for clindamycin phosphate arm it was 88.4% (P = 0.218). The adverse events were similar in both groups. CONCLUSIONS: Trospectomycin was as effective as clindamycin, when both were combined with aztreonam, in treatment of obstetric and gynecologic infections.
ABSTRACT
Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials. Atevirdine is most soluble at a pH of < 2, and therefore, normal gastric acidity is most likely necessary for optimal bioavailability. Because of the rapid development of resistance in vitro, atevirdine is being evaluated in combination with didanosine and/or zidovudine in both two- and three-drug combination regimens. To examine the influence of concurrent didanosine (buffered tablet formulation) on the disposition of atevirdine, 12 human immunodeficiency virus type 1-infected subjects (mean CD4+ cell count, 199 cells per mm3; range, 13 to 447 cells/mm3) participated in a three-way, partially randomized, crossover, single-dose study to evaluate the pharmacokinetics of didanosine and atevirdine when each drug was given alone (treatments A and B, respectively) versus concurrently (treatment C). Concurrent administration of didanosine and atevirdine significantly reduced the maximum concentration of atevirdine in serum from 3.45 +/- 2.8 to 0.854 +/- 0.33 microM (P = 0.004). Likewise, the mean atevirdine area under the concentration-time curve from 0 to 24 h after administration of the combination was reduced to 6.47 +/- 2.2 microM.h (P = 0.004) relative to a value of 11.3 +/- 4.8 microM.h for atevirdine alone. Atevirdine had no statistically significant effect on the pharmacokinetic parameters of didanosine. Concurrent administration of single doses of atevirdine and didanosine resulted in a markedly lower maximum concentration of atevirdine in serum and area under the concentration-time curve, with a minimal effect on the disposition of didanosine. It is unknown whether an interaction of similar magnitude would occur under steady-state conditions; thus, combination regimens which include both atevirdine and didanosine should be designed so that their administration times are separated. Since the duration of the buffering effect of didanosine formulations is unknown, atevirdine should be given prior to didanosine.
Subject(s)
Antiviral Agents/pharmacology , Didanosine/pharmacology , HIV Infections/metabolism , HIV-1 , Piperazines/pharmacokinetics , Adolescent , Adult , Antiviral Agents/pharmacokinetics , Cross-Over Studies , Didanosine/pharmacokinetics , Drug Interactions , Female , Half-Life , Humans , Intestinal Absorption/drug effects , Male , Middle AgedSubject(s)
Acquired Immunodeficiency Syndrome/complications , Antifungal Agents/therapeutic use , Cryptococcosis/drug therapy , Meningitis/drug therapy , Triazoles/therapeutic use , Adult , Amphotericin B/therapeutic use , Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Cryptococcosis/etiology , Fluconazole , Humans , Male , Meningitis/etiology , Triazoles/blood , Triazoles/cerebrospinal fluidABSTRACT
Fluconazole is a new bis-triazole derivative proven highly effective against Candida in various animal models. To determine its potential use in exogenous fungal endophthalmitis, 13 New Zealand white rabbits were given intravitreal injections of up to 100 micrograms/0.1 mL of the antifungal. All eyes underwent biomicroscopy, ophthalmoscopy and electroretinography before and after the procedure. No evidence of toxic intraocular effects was detected with these techniques or on light microscopy, performed 8 days after injection. The results suggest that fluconazole has potential application in the treatment of exogenous fungal endophthalmitis.
Subject(s)
Antifungal Agents/toxicity , Eye/drug effects , Triazoles/toxicity , Animals , Electroretinography , Fluconazole , Microscopy/methods , Ophthalmoscopy , Rabbits , Triazoles/administration & dosage , Vitreous BodyABSTRACT
Sixty-two adults who underwent orthotopic liver transplantations between February 1981 and June 1983 were followed for a mean of 170 days after the operation. Twenty-six patients developed 30 episodes of significant fungal infection. Candida species and Torulopsis glabrata were responsible for 22 episodes and Aspergillus species for 6. Most fungal infections occurred in the first month after transplantation. In the first 8 weeks after transplantation, death occurred in 69% (18/26) of patients with fungal infection but in only 8% (3/36) of patients without fungal infection (P less than 0.0005). The cause of death, however, was usually multifactorial, and not solely due to the fungal infection. Fungal infections were associated with the following clinical factors: administration of preoperative steroids (P less than 0.05) and antibiotics (P less than 0.05), longer transplant operative time (P less than 0.02), longer posttransplant operative time (P less than 0.01), duration of antibiotic use after transplant surgery (P less than 0.001), and the number of steroid boluses administered to control rejection in the first 2 posttransplant months (P less than 0.01). Patients with primary biliary cirrhosis had fewer fungal infections than patients with other underlying liver diseases (P less than 0.05). A total of 41% (9/22) of Candida infections resolved, but all Aspergillus infections ended in death.
Subject(s)
Liver Transplantation , Mycoses/etiology , Adult , Aspergillosis/etiology , Aspergillosis/mortality , Candidiasis/etiology , Candidiasis/mortality , Cryptococcosis/etiology , Cryptococcosis/mortality , Female , Graft Rejection , Humans , Male , Mucormycosis/etiology , Mucormycosis/mortality , Mycoses/mortality , Reoperation , Steroids/therapeutic use , Time FactorsABSTRACT
The clinical, radiographic, and pathologic correlates of acute respiratory failure due to Pneumocystis carinii pneumonia were studied in 12 renal transplant patients treated with cyclosporin (CS) and prednisone. Six patients required only supplemental oxygen, while the other six patients developed the adult respiratory distress syndrome (ARDS) requiring prolonged mechanical ventilation despite similar predisposing factors and prompt initiation of therapy. Ten (83%) patients survived. Increased frequency of human leukocyte antigen (HLA) DR6 was noted in six of the 11 patients tested. The resolution of radiographic infiltrates was significantly slower in ARDS patients; however, there was no apparent difference in the severity of early alveolar damage between the two groups. There was also no association between the development of ARDS due to P. carinii pneumonia and the mean daily dose of CS and prednisone, the presence of cytomegalovirus infection or pneumonia, HLA-DR6 antigen, or initial hypoxemia.
Subject(s)
Pneumonia, Pneumocystis , Respiratory Insufficiency , Acute Disease , Adult , Aged , Female , Humans , Immunosuppression Therapy , Kidney Transplantation , Male , Middle Aged , Oxygen Inhalation Therapy , Pneumonia, Pneumocystis/diagnostic imaging , Pneumonia, Pneumocystis/pathology , Pneumonia, Pneumocystis/physiopathology , Pulmonary Alveoli/microbiology , Pulmonary Alveoli/pathology , Radiography , Respiration, Artificial , Respiratory Distress Syndrome/diagnostic imaging , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/pathology , Respiratory Insufficiency/diagnostic imaging , Respiratory Insufficiency/pathology , Respiratory Insufficiency/physiopathologyABSTRACT
Intra-abdominal actinomycosis is rarely suspected and is difficult to diagnose. A 46-year-old woman with intra-abdominal actinomycosis is described in whom the condition was first suspected when sulfur granules were found in her urine. The infection had involved her bladder but not her kidneys.
Subject(s)
Abdomen , Actinomycosis/urine , Sulfur/urine , Abdomen/microbiology , Actinomyces/isolation & purification , Actinomycosis/drug therapy , Actinomycosis/microbiology , Bacteroides/isolation & purification , Clindamycin/therapeutic use , Female , Humans , Laparotomy , Middle Aged , Penicillin G/therapeutic use , Urine/microbiologyABSTRACT
Fourteen of 156 renal-transplant recipients treated with cyclosporine and steroids developed Pneumocystis carinii-related pneumonia (PCP) over a 19-month period. This was a significant change from past experience with this disease in renal-transplant patients receiving azathioprine and steroids (six cases among 179 patients from 1977 to 1981). Epidemiological investigation failed to implicate either person-to-person or nosocomial spread of infection. Cases of PCP occurred more frequently in males. Twelve patients (86%) had onset of disease in the third or fourth months after transplantation. Comparison of cases to matched controls revealed that the cases had received lower doses of steroids and had a higher incidence of cytomegalovirus infection. This suggested that the cases may have been more effectively immunosuppressed than the controls. After institution of prophylaxis with trimethoprim-sulfamethoxazole, no further cases of PCP developed.